Please login to the form below

Not currently logged in
Email:
Password:

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

IMV preps pivotal trials for ovarian cancer T cell therapy

IMV preps pivotal trials for ovarian cancer T cell therapy

B-cell lymphoma (DLBCL) and another spanning multiple solid tumour types.

Latest news

More from news
Approximately 9 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).  According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics